AN2 Therapeutics ANTX 深 滬
等待開盤 09-17 09:30:00 美东时间
5.34
-0.020
-0.37%
華盛通- 最 高5.44
- 今 開5.38
- 成交量 14.60万股
- 最 低 5.295
- 昨 收 5.36
- 總市值 2.02亿
- 52周最高 7.19
- 市盈率 靜 --
- 換手率 0.39%
- 52周最低 1.00
- 委 比 96.28%
- 總股本 3773.62万
- 歷史最高 23.58
- 量 比 0.83
- 振 幅 2.71%
- 歷史最低 0.87
- 每 手 1
- 風險率 1.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AN2 Therapeutics To Reveal Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera At The SOHO 2026 Annual Meeting
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the deve...
09-01 06:06
AN2 Therapeutics appoints biotech veteran Cameron Trenor as CMO
AN2 Therapeutics (ANTX) appointed Cameron Trenor, M.D., as chief medical officer, bringing more than two decades of clinical and drug development experience. Trenor most recently served as chief medic...
08-24 19:44
QUICK SPARK: Russell 2000 Hits New Record Highs, Beats Nasdaq 100 In 2026
The Russell 2000 index just hit a new record high on Thursday, climbing past 3,060 points. The small-cap index, tracked by the iShares Russell 2000 ETF (NYSE:IWM), is now up over 23% year to date, edging ahead of the Nasdaq 100’s 19% gain. The biggest Russell 2000 winners thus far this year are: Bra...
08-13 23:29
AN2 Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
AN2 Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
08-12 23:34
AN2 Therapeutics Q2 EPS $(0.18) Beats $(0.27) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 14.29 percent increase over losses of $(0.21) per share from the same period last year.
08-12 04:33
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
Guggenheim Initiates Coverage On AN2 Therapeutics with Buy Rating, Announces Price Target of $9
Guggenheim analyst Brad Canino initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Buy rating and announces Price Target of $9.
07-20 20:03
AN2 Therapeutics Announces Results From Two Studies Evaluating Oral CPSF3 Inhibitor, AN2-502998, For Treatment Of Chronic Chagas Disease Caused By Infection With Parasite T. Cruzi
Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humansPhase 1 First-In-Human (FIH) study showed
06-04 19:09
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
